Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tbi + fludarabine
- Development stage
- Unknown
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, External Beam Radiation
01
Overview
TBI + fludarabine is a combination conditioning regimen used primarily before allogeneic hematopoietic cell transplantation (allo-HCT), especially in patients with acute lymphoblastic leukemia (ALL) and other hematologic malignancies. The regimen combines total body irradiation (TBI), which delivers ionizing radiation to the entire body to eradicate malignant cells and suppress the immune system, with fludarabine, a purine analog chemotherapeutic agent that inhibits DNA synthesis by interfering with DNA polymerase and ribonucleotide reductase. This combination can be used as either myeloablative or reduced-intensity conditioning depending on TBI dose and patient characteristics. The goal is to maximize disease eradication while minimizing toxicity prior to stem cell transplantation[1][3][4][5].
- Other names
- tbi + flutotal body irradiation + fludarabinetbi/fludarabine
02
Targets
DNA polymerase family
Beyond the preview
Go deeper on tbi + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tbi + fludarabine.